Navigation Links
Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia
Date:2/19/2008

- Establishes Plan for Biomarker Study -

MONTVALE, N.J., Feb. 19 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY) today announced that it plans to conduct a clinical study of MEM 3454, the Company's lead nicotinic alpha-7 partial agonist, on two biomarkers of schizophrenia, P50 sensory gating and mismatch negativity, in patients with schizophrenia. The biomarker study, and additional formulation and manufacturing activities for MEM 3454, will be funded by Roche, under the companies' collaboration for the development of nicotinic alpha-7 receptor agonists.

"This new study will greatly enhance our ability to measure and predict the efficacy of MEM 3454 and other compounds in the nicotinic alpha-7 receptor program," said Stephen Murray, MD, Ph.D, Chief Medical Officer of Memory Pharmaceuticals Corp. "The study should be underway this summer with data available by early 2009. The biomarker data, together with the results of our ongoing Phase 2a study in CIAS, will help with the design of later-stage trials in schizophrenia."

The biomarker study will enroll approximately 12 patients with stable schizophrenia who are receiving atypical antipsychotic therapy. Subjects will be randomized to receive MEM 3454 and placebo in a 5-way cross-over design. Each subject will participate in 5 treatment periods. During each period, subjects will receive single doses of 1 mg, 5 mg, 15 mg, or 50 mg of MEM 3454 or placebo, with a 4-day wash-out period between each treatment period. The primary objective of the trial is to study P50 sensory gating and mismatch negativity as potential efficacy biomarkers for nicotinic alpha-7 agonists, such as MEM 3454, in schizophrenia. P50 sensory gating and mismatch nega
'/>"/>

SOURCE Memory Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Experimental Drug Ketasyn(TM) Improves Memory in Age-Associated Memory Impairment Study
2. Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908
3. Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimers Disease
4. Experts Call for Widespread Use of Memory Screenings and Emphasize Value of Early Detection of Dementia
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Fla. , Aug. 3, 2015  Charleston ... initiation of its second clinical development program with ... candidate, CL-H1T.  CL-H1T contains fast-dissolving ... being developed as a treatment for migraine headache ... "Many patients with migraine headaches also ...
(Date:8/3/2015)... Immune Pharmaceuticals, Inc. ("Immune") (NASDAQ: IMNP ... , will present live at VirtualInvestorConferences.com on August 6, ... 11:30AM EDT LINK:    http://tinyurl.com/aug6-pre-imnp ... investors are invited to ask the company questions in ... as the association,s "virtual trade booth." If attendees are ...
(Date:8/3/2015)...  EnteroMedics Inc. (NASDAQ: ETRM ), the developer of ... diseases and other gastrointestinal disorders, today announced that ... Board of Directors, effective July 31, 2015.  Ms. McDougal ... 2018 annual meeting or until her successor is elected ... an executive capacity in the healthcare industry for more ...
Breaking Medicine Technology:Charleston Laboratories, Inc. Initiates Patient Enrollment in a Phase 1 Study of Charleston's Second Product, CL-H1T 2Immune Pharmaceuticals to Webcast Live at VirtualInvestorConferences.com August 6 2EnteroMedics Announces Appointment of Lori C. McDougal to the Board of Directors 2EnteroMedics Announces Appointment of Lori C. McDougal to the Board of Directors 3
... ITMN ) today announced that it will ... in idiopathic pulmonary fibrosis (IPF) prior,to market open on ... and webcast, with accompanying slide presentation, to discuss results,from ... PST) on Tuesday,February 3. , ...
... MENLO PARK, Calif., Feb. 2 Evalve, Inc., ... percutaneous repair of cardiac valves,announced today the start ... Study of the MitraClip(R) System) study, a continued ... in the United,States as a non-surgical treatment option ...
Cached Medicine Technology:InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3 2First U.S. Patients Enrolled in the REALISM Continued Access Study 2First U.S. Patients Enrolled in the REALISM Continued Access Study 3
(Date:8/3/2015)... Va. (PRWEB) , ... August 03, 2015 , ... The ... the use of health IT to create efficiencies in healthcare information exchange, announced the ... letters to the Health and Human Services (HHS) Secretary, WEDI shared survey results ...
(Date:8/3/2015)... ... August 03, 2015 , ... Bayer has agreed to pay ... claims in which a claimant alleged to have suffered an arterial blood clot including ... control pills, Yaz, Yasmin and Ocella, has been ongoing for well-over five years. In ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... services to contract research organisations (CROs) for a slew of benefits, allowing them ... research and operations, boost quality with cost-effective utilisation of resources, get access to ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... retailer of nutritional supplements, has officially opened the polls for their eleventh ... the following categories:, ,     Brand of the Year (BPI ...
(Date:8/3/2015)... ... ... The art of preparing and cooking food comes naturally to some. For ... Nasreen Zereshki was extremely eager to cook Persian cuisine. Now that she is skilled ... Kitchen with the world. , Since Americans tend to be undereducated about Persian cuisine, ...
Breaking Medicine News(10 mins):Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 2Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 3Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 4Health News:Bayer Agrees To Settle Yaz Aterial Blood Clot Lawsuits 2Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 2Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 3Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 2Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 3Health News:Persian Cuisine: Colorful and Extremely Healthy 2
... (HealthDay News) -- Drug users who inject themselves with ... than those abusing other drugs, new research reveals. ... in a mixture of social, structural and neurobiological factors, ... Health in New York City and the University of ...
... Dennis Thompson HealthDay Reporter , FRIDAY, Dec. 30 ... diabetes when she was 19 years old and a student ... in Montgomery Village, Md., Keys had been suffering the classic ... "That prompted me to just go to the doctor," she ...
... 29 (HealthDay News) -- There are many ways to prevent ... easiest ways is also one of the most important: proper ... when people travel and get together for parties and other ... Safety noted. "Hand-washing is the single most effective way ...
... Women recently diagnosed with breast cancer have higher survival ... the American Cancer Society. However, survivors continue to face ... as many as 50 percent of breast cancer survivors ... Sinclair School of Nursing say a meditation technique can ...
... , THURSDAY, Dec. 29 (HealthDay News) -- In some cases, ... "silent strokes," new research suggests. Such strokes, which may ... dead brain cells, and are found in roughly 25 percent ... aspect of this study of memory loss in the elderly ...
... HealthDay Reporter , THURSDAY, Dec. 29 (HealthDay News) -- If ... blood tests, an imaging test like an MRI or ultrasound, ... really necessary?" you might have wondered. That,s a question ... of evidence suggests that overuse of diagnostic testing may be ...
Cached Medicine News:Health News:Meth Users Much More Likely to Try Suicide 2Health News:A Life-Saving Lesson That Took Decades to Learn 2Health News:Hand-Washing Key to Stopping Spread of Disease 2Health News:Breast cancer survivors benefit from practicing Mindfulness-based Stress Reduction 2Health News:'Silent Strokes' Linked to Memory Loss in Elderly: Study 2Health News:Is American Medicine Too Test Happy? 2Health News:Is American Medicine Too Test Happy? 3
Optimal solution for normal acetabulum....
The Biopro All Poly cup is a uniquely designed UHMWPE acetabular cup....
The Pe-Plus offers an additional clinical option for replacing the acetabulum....
BatCup cotyloid implant, designed for use in revision surgery, is an hemispherical metal cup, with grooves on the edges that house locking flanges, which are attached to the iliac bone by cancellous ...
Medicine Products: